Exploring the Potential Drug Target and Biomarker KCNK12: A Pore Domain Halothane-Inhibited Potassium Channel 2

Target Name: KCNK12

NCBI ID: G56660

KCNK12

Exploring the Potential Drug Target and Biomarker KCNK12: A Pore Domain Halothane-Inhibited Potassium Channel 2

Potassium channels are essential for maintaining the resting membrane potential of eukaryotic cells, and their regulation is critical for various physiological processes, including muscle and nerve function, as well as neurotransmitter release. The pore domain of potassium channels is a well-established family of channels that play a central role in intracellular signaling, including modulation of ion channels by various ligands. The Tandem Pore Domain (TPD) of potassium channels is a unique feature that enables these channels to exist in a alternating open and closed state, allowing for increased channel stability and modulation by ligands. The TPD is also involved in modulation by various diseases, including neurological and psychiatric disorders.

KCNK12, a member of the TPD family, is a potassium channel that has been identified as a potential drug target and biomarker. The function of KCNK12 is highly conserved among various species, and its structure suggests that it may be a good candidate for drug development. In this article, we will explore the molecular mechanism of KCNK12 and its potential as a drug target and biomarker.

Molecular Mechanism of KCNK12

The molecular mechanism of KCNK12 is well understood, and its function is primarily determined by its TPD. The TPD is a transmembrane protein that is composed of two distinct domains: an N-terminal domain that contains a putative ion-channel-active catalytic site and a C-terminal domain that contains a unique disulfide-linking system (DLS). The N-terminal domain contains a nucleotide-binding site (NBS) that is responsible for channel stability and modulation by various ligands, while the C-terminal domain contains a series of conserved non-coding regions that are involved in channel stability and modulation by diseases.

KCNK12 is a type I member of the TPD family, which includes various isoforms that differ in their N-terminal and C-terminal domains. These isoforms are characterized by a unique combination of N-terminal and C-terminal domains that give them unique features and functions. The N-terminal domain of KCNK12 contains a nucleotide-binding site (NBS) that is responsible for channel stability and modulation by various ligands, including inhibitors such as halothane. The C-terminal domain of KCNK12 contains a series of conserved non-coding regions that are involved in channel stability and modulation by diseases.

KCNK12 has been shown to play a critical role in various physiological processes, including neuronal signaling, neurotransmitter release, and ion transport. It is highly expressed in the brain and nervous system, and its function is highly conserved among various species. Several studies have demonstrated that KCNK12 is involved in modulation by various diseases, including neurological and psychiatric disorders.

Potential Drug Target and Biomarker

The potential drug target of KCNK12 is its unique TPD feature, which allows it to exist in a alternating open and closed state and to be modulated by various ligands, including inhibitors such as halothane. This feature makes it an attractive candidate for drug development, as it allows for increased channel stability and modulation by ligands, which can be used to treat various neurological and psychiatric disorders.

In addition to its potential as a drug target, KCNK12 has also been identified as a potential biomarker for various diseases, including neurological and psychiatric disorders. Its expression is highly conserved among various species, and its function is well understood, making it an attractive candidate for use as a biomarker for various diseases.

Conclusion

In conclusion, KCNK12 is a unique member of the TPD family that has been identified as a potential drug target and biomarker. Its unique TPD feature and its function in various physiological processes make it an attractive candidate for drug development. Additionally, its conservation in various species makes it an attractive candidate for use as a biomarker for various diseases. Further studies are needed to fully understand its potential as a drug target and biomarker.

Protein Name: Potassium Two Pore Domain Channel Subfamily K Member 12

Functions: Probable potassium channel subunit. No channel activity observed in heterologous systems. May need to associate with another protein to form a functional channel (By similarity)

The "KCNK12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNK12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets